4-氯甲基-[1,3]二噁烷 | 1121-62-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二恶烷
• 中文名称: 4-氯甲基-[1,3]二噁烷
• 英文名称: 4-chloromethyl-1,3-dioxane
• 英文别名: 4-Chlormethyl-[1,3]dioxan；1-chloro-2,4-methylenedioxybutane；4-Chloromethyl-[1,3]dioxane；4-(chloromethyl)-1,3-dioxane
• CAS: 1121-62-6
• 化学式: C₅H₉ClO₂
• mdl: MFCD00622396
• 分子量: 136.578
• InChiKey: GKUCVLXFBHZZDE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  4-氯甲基-[1,3]二噁烷 在 potassium carbonate 、 三乙胺 作用下， 反应 60.5h， 生成 1-[([1,3]Dioxan-4-ylmethyl-phenyl-carbamoyl)-methyl]-pyridinium; chloride
  参考文献：
  名称：

  Synthesis of N-substituted 4-aminomethyl-1,3-dioxanes

  摘要：

  DOI：

  10.1007/bf01171282
• 作为产物：
  描述：

  1,3-二恶烷-4-甲醇 在 吡啶 、 氯化亚砜 作用下， 反应 5.0h， 生成 4-氯甲基-[1,3]二噁烷
  参考文献：
  名称：

  1,2,4-丁三醇与羰基化合物的缩合反应及羟烷基-1,3-二氧杂环丁烷的反应

  摘要：

  通过使1,2,4-丁三醇与低聚甲醛反应制备2-（1,3-二氧杂戊-4-基）乙醇和1,3-二氧杂-4-基甲醇的异构体的混合物。对该混合物进行O-烷基化，O-酰化，与异氰酸苯酯缩合，以及用OH基团取代Cl。估计了甘油和1,2,4-丁三醇的丙酮衍生物在与烯丙基氯和苄基氯反应中的相对活性。

  DOI：

  10.1134/s107036321808008x

文献信息

• [EN] 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS<br/>[FR] PYRAZOLO[1,5-A] PYRAZINES SUBSTITUÉES EN 4,6 EN TANT QU'INHIBITEURS DE LA JANUS KINASE
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2016090285A1

  公开（公告）日：2016-06-09

  Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3 and R4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.

  公式I的化合物及其立体异构体和药学上可接受的盐和溶剂化合物，在其中R1、R2、R3和R4具有规范中给定的含义，是一种或多种JAK激酶的抑制剂，并且在治疗JAK激酶相关疾病和疾病方面非常有用，如自身免疫疾病、炎症性疾病、移植器官、组织和细胞的排斥反应，以及血液学疾病和恶性肿瘤及其并发症。
• Halogenated dioxolane tranquilizers
  申请人：ICI United States Inc.

  公开号：US03996376A1

  公开（公告）日：1976-12-07

  Halogenated dioxolane compounds having perhalogenated groups in the 2-position and other substituted groups, for example, carbamate and nitrate in the 4 and/or 5-position are disclosed. These compounds are useful as tranquilizers.

  卤代二噁烷化合物，在2位具有全氟代基和其他取代基，例如在4和/或5位的氨基甲酸酯和硝酸酯被披露。这些化合物可用作镇定剂。
• Carbostyril derivative
  申请人：Otsuka Pharmaceutical Co.

  公开号：US05401740A1

  公开（公告）日：1995-03-28

  The novel carbostyril derivative represented by the general formula (1) ##STR1## [in the formula, A, R.sup.1, R.sup.2 and the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton have the same definitions as above] has an excellent platelet aggregation inhibitory activity, a phosphodiesterase inhibitory activity, a venticular contraction activity (a positive contraction activity), an anti-ulcer activity, an anti-inflammatory activity, a cerebral blood flow increasing activity, a thrombus dissociation activity, a thromboxane A.sub.2 antagonism activity, etc. The carbostyril derivative of the present invention is characterized in that it exhibits the above activities for a long time, is low in toxicity (particularly low in toxicity to hearts of cardiovascular hyperplasia, myocardipathy, etc.), and is low in circulation activities such as heart rate increasing activity, blood pressure decreasing activity and the like. Also, the carbostyril derivative of the present invention has advantages in that it is easily absorbed by the intestinal tract and easily migrates into blood. Therefore, the carbostyril derivative of the present invention can be used most suitably as a preventive and remedy for thrombi such as apoplexia, cerebral infarction, myocardial infarction and the like, a cerebral circulation improving agent, an anti-inflammatory agent, an anti-asthmatic agent, a cardiotonic agent and a phosphodiesterase inhibitory agent.

  通式（1）所表示的新型碳基苯并咪唑衍生物 ##STR1## [在公式中，A，R.sup.1，R.sup.2和碳基苯并咪唑骨架中3-和4-位之间的碳-碳键具有与上述相同的定义] 具有出色的血小板聚集抑制活性，磷酸二酯酶抑制活性，室性收缩活性（阳性收缩活性），抗溃疡活性，抗炎活性，增加脑血流活性，溶解血栓活性，血栓素A.sub.2拮抗活性等。本发明的碳基苯并咪唑衍生物的特点在于它表现出上述活性长时间持续，毒性低（特别是对心血管增生，心肌病等心脏毒性低），循环活性如心率增加活性，降低血压活性等也低。此外，本发明的碳基苯并咪唑衍生物具有易被肠道吸收且易进入血液的优点。因此，本发明的碳基苯并咪唑衍生物最适用于预防和治疗像中风，脑梗塞，心肌梗塞等血栓，改善脑循环的药物，抗炎药，抗哮喘药，强心剂和磷酸二酯酶抑制剂。
• CARBOSTYRIL DERIVATIVES
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP0450066A1

  公开（公告）日：1991-10-09

  This invention relates to carbostyril derivatives represented by general formula (1), a process for their preparation, and an agent for inhibiting agglutination of platelets containing them as an active ingredient, wherein A represents a lower alkylene group, R1 represents a substituted or unsubstituted cycloalkyl-lower alkyl group, a cycloalkyl group, a tetrahydropyranyl* lower alkyl group, a lower alkylenedioxy-substituted lower alkyl group, a substituted phenyl-lower alkyl group or a lower alkyl-substituted piperidinyl-lower alkyl group, R2 represents a substituted or unsubstituted 5- or 6-membered, saturated or unsaturated heterocyclic-lower alkyl group, a tetrahydropyranylthio-lower alkyl group, a pyridylthio-lower alkyl group, a lower alkylene-dioxy-substituted lower alkyl group or a substituted or unsubstituted lower alkyl group, and the carbon-to-carbon bond between the 3- position and the 4-position of the carbostyril skeleton represents either a single or a double bond.

  本发明涉及通式(1)代表的碳化二氢吡啶衍生物、其制备工艺以及含有其作为活性成分的抑制血小板凝集的制剂，其中A代表低级亚烷基，R1代表取代或未取代的环烷基-低级烷基、环烷基、四氢吡喃基*低级烷基、低级亚烷基-二氧基取代的低级烷基、取代的苯基-低级烷基或低级烷基-取代的哌啶基-低级烷基、R2 代表取代或未取代的 5 或 6 元、饱和或不饱和杂环低级烷基、四氢吡喃硫基低级烷基、吡啶硫基低级烷基、亚烷基二氧基取代的低级烷基或取代或未取代的低级烷基，碳四吡啶骨架的 3 位和 4 位之间的碳-碳键代表单键或双键。
• PHARMACEUTICAL COMPOSITION COMPRISING A JAK-INHIBITING 4,6-SUBSTITUTED-PYRAZOLO[1,5-A]PYRAZINE COMPOUND
  申请人：Array Biopharma Inc.

  公开号：EP3878451A1

  公开（公告）日：2021-09-15

  Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3 and R4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.

  式 I 的化合物： 及其立体异构体和药学上可接受的盐及溶液，其中 R1、R2、R3 和 R4 具有说明书中给出的含义，是一种或多种 JAK 激酶的抑制剂，可用于治疗与 JAK 激酶相关的疾病和紊乱，如自身免疫性疾病、炎症性疾病、移植器官、组织和细胞的排斥反应，以及血液病和恶性肿瘤及其并发症。